ライフサイエンスコーパス: CMV infection

1 and consequently protected mice from murine CMV infection.

2 ltisystem autoimmunity and susceptibility to CMV infection.

3 crease in the risk of clinically significant CMV infection.

4 V infection in 1976 recipients free of prior CMV infection.

5 odel of CD8(+) T cell differentiation during CMV infection.

6 ere within ranges observed following natural CMV infection.

7 ors in the blood being a strong correlate of CMV infection.

8 ion occurring in human NK cells during human CMV infection.

9 on in vitro and in vivo in response to mouse CMV infection.

10 POT assay is able to predict protection from CMV infection.

11 ction, and during a persistent/latent murine CMV infection.

12 n of anti-CMV immunity or increased risk for CMV infection.

13 ess responses that are capable of inhibiting CMV infection.

14 of the plant, while not having any effect on CMV infection.

15 ated with premature rupture of membranes and CMV infection.

16 s the only small animal model for congenital CMV infection.

17 oint of this nested study was time to infant CMV infection.

18 e during immune maturation following primary CMV infection.

19 toxin as an effective compound that inhibits CMV infection.

20 of this immunoglobuline preparation against CMV infection.

21 ies using the guinea pig model of congenital CMV infection.

22 fe and promising approach against congenital CMV infection.

23 ment for ganciclovir-resistant or refractory CMV infection.

24 tem and may have a direct relevance to human CMV infection.

25 otential to suppress the indirect effects of CMV infection.

26 ation is at a particularly increased risk of CMV infection.

27 e critical during the early viremic phase of CMV infection.

28 AS-STING pathway in the initial detection of CMV infection.

29 l some of the direct and indirect effects of CMV infection.

30 elta2(neg) gammadelta T cells in controlling CMV infection.

31 ated in relation to treatment outcome during CMV infection.

32 Of 101,111 infants, 328 (0.3%) had postnatal CMV infection.

33 ntenance is disrupted by an episode of acute CMV infection.

34 li and more robust adaptive responses during CMV infection.

35 ent of maternal HIV infection, but not early CMV infection.

36 linical findings consistent with symptomatic CMV infection.

37 act of vaccination for preventing congenital CMV infection.

38 use pipeline to identify DNA consistent with CMV infection.

39 imated the true genetic diversity in primary CMV infection.

40 (Nos2) are susceptible to the related murine CMV infection.

41 hts into the virologic determinants of early CMV infection.

42 ansplant recipients and associated with late CMV infection.

43 such as death, graft rejection, bacterial or CMV infections.

44 34%) patients, and 17/41 discontinued due to CMV infections.

45 erapy in transplant patients with refractory CMV infections.

46 women including 57 primary and 23 nonprimary CMV infections.

47 ld be adopted to address the complexities of CMV infections.

48 "adaptive" responses after cytomegalovirus (CMV) infection.

49 ) is associated with latent cytomegalovirus (CMV) infection.

50 ctious exposures, including cytomegalovirus (CMV) infection.

51 .001) and had a higher 1-year probability of CMV infection (0.89 vs 0.69; P < .001).

52 We matched infants with postnatal CMV infection 1:1 to comparison infants using propensity

53 Twelve (14%) developed CMV infection: 1 during prophylaxis and 11 during follow

54 mulative incidence of clinically significant CMV infection (35% vs 5%; P = .02; and 40% vs 12%; P = .

55 day CMI risk stratification better predicted CMV infection (81.3% vs 9.1%; OR, 43.33 [95% CI, 7.89-23

56 We demonstrated that acute CMV infection abrogated transplantation tolerance during

57 Postnatal CMV infection acquired by exposure to raw maternal milk

58 In preterm infants cytomegalovirus (CMV) infection acquired through maternal milk has been r

59 ATG dose was associated with a lower risk of CMV infection (adjusted hazard ratio [aHR]: 0.63; 95% co

60 In the logistic regression model, CMV infection (adjusted odds ratio [aOR], 4.6 [95% confi

61 ciated with CMV infection occurred in 4, and CMV infection adversely affected patient survival (P = 0

62 to the partial protection against postnatal CMV infection afforded by maternal antibodies, and they

63 (PC)-mediated epithelial cell entry decrease CMV infection after HCT, samples were analyzed from a ra

64 e also demonstrate that long-term control of CMV infection after HSCT is primarily mediated through t

65 Limited clinical data exist regarding CMV infection after IIT/MVT.

66 lls was observed in patients who experienced CMV infection after LTx.

67 Prophylaxis effectively prevents CMV infection after solid organ transplantation (SOT) bu

68 The most significant risk for developing CMV infection after transplant depends upon donor (D) an

69 n the prevention of primary cytomegalovirus (CMV) infection after hematopoietic cell transplantation

70 Control of cytomegalovirus (CMV) infection after solid organ transplantation (SOT) r

71 ssential for the control of cytomegalovirus (CMV) infection after transplantation.

72 strategies can be adopted to treat resistant CMV infections, albeit no randomized clinical trials exi

73 splant PCP and 3 variables: cytomegalovirus (CMV) infection, allograft rejection, and prophylaxis.

74 CMV infection also was associated with reduced CD8(+) T

75 e used Cox regression to compare the risk of CMV infection and acute rejection (AR) among KT recipien

76 model was applied, with clinically relevant CMV infection and any CMV infection as time-dependent va

77 model was applied, with clinically relevant CMV infection and any CMV infection as time-dependent va

78 significant association was observed between CMV infection and CAV, except for patients who experienc

79 significant association was observed between CMV infection and CAV, except for patients who experienc

80 m was to investigate the association between CMV infection and disease and severe HCV recurrence (com

81 outcomes in clinical trials, definitions of CMV infection and disease were developed and most recent

82 ive graft may offer an advantage in terms of CMV infection and disease.

83 sk of acquisition of an exogenous nonprimary CMV infection and fetal transmission.

84 may help bridge the gap in understanding how CMV infection and immunity are linked to increased cardi

85 nt(-); D(+)R(-)) are at high risk for active CMV infection and increased mortality; however, the immu

86 ng mRNA translation has a dramatic impact on CMV infection and proliferation.

87 s the only small animal model for congenital CMV infection and recapitulates disease symptoms (e.g.,

88 As the virus genetic diversity in primary CMV infection and the changes over time remain incomplet

89 ly discriminatory indicator of carrying both CMV infection and the relevant HLA type.

90 CD8(+) T cell repertoires following neonatal CMV infection and thus have important implications for t

91 s to analyze risk factors for posttransplant CMV infection and to assess the efficacy and validity of

92 sults suggest new approaches both to curtail CMV infection and to purge the virus from organ transpla

93 among the first immune cells that respond to CMV infection and use germ line-encoded NK cell receptor

94 l models of viral dynamics upon initial oral CMV infection and validated them using clinical shedding

95 stinct assays, was higher in infants without CMV infection and was moderately associated with delayed

96 vir for both the prevention and treatment of CMV infections and disease in transplant recipients has

97 transplant recipients >=12 years old with RR CMV infections and plasma CMV deoxyribonucleic acid (DNA

98 on the association between cytomegalovirus (CMV) infection and cardiac allograft vasculopathy (CAV)

99 on the association between cytomegalovirus (CMV) infection and cardiac allograft vasculopathy (CAV)

100 candidate vaccines against cytomegalovirus (CMV) infection and disease are in development.

101 es specific tools to combat cytomegalovirus (CMV) infection and helps illuminate a general path to ac

102 in patients with concurrent cytomegalovirus (CMV) infection and inflammatory bowel disease (IBD).

103 CMV-infection and -disease were successfully managed wit

104 series of 4 lung transplant recipients with CMV-infection and treatment failure upon standard care d

105 The symptomatic manifestations of CMV infection are compounded by adverse indirect effects

106 The current FDA-approved treatments for CMV infection are intended to be virus specific, yet the

107 MV infection born to mothers with nonprimary CMV infection are similar to infants born after a primar

108 entified patients who were protected against CMV infection as long as they had no graft-versus-host d

109 th clinically relevant CMV infection and any CMV infection as time-dependent variables.

110 th clinically relevant CMV infection and any CMV infection as time-dependent variables.

111 The mAbs inhibit CMV infection at a post-attachment step by interacting w

112 ve study included patients diagnosed with GI-CMV infection at Siriraj Hospital (Bangkok, Thailand) du

113 n group) revealed prevalent cytomegalovirus (CMV) infection at diagnosis in childhood ALL, demonstrat

114 studies of such a vaccine against congenital CMV infection based on a virus with a targeted deletion

115 in the present study no difference in murine CMV infection between Ncr1(gfp/pfp) and wild-type (WT) m

116 ory abnormalities in infants with congenital CMV infection born to mothers with nonprimary CMV infect

117 r morbidities and accumulate in both HIV and CMV infections, both of which are associated with increa

118 novel cell-targeting antiviral that inhibits CMV infection by decreasing the synthesis of viral prote

119 PC-entry nAb titers (P = .07) and decreased CMV infection by PCR at viral load cutoffs of >=1000 and

120 ich are important for effectively inhibiting CMV infection by targeting the expression of immediate-e

121 e estimated the likelihood of transient oral CMV infections by comparing their observed frequency to

122 neonates were screened for cytomegalovirus (CMV) infection by polymerase chain reaction (PCR) at bir

123 isions made during the acute phase of murine CMV infection can alter the level of memory inflation by

124 how adaptive NK cells arising in response to CMV infection can escape MDSC-mediated suppression, and

125 on of ganR- and ganciclovir-sensitive (ganS) CMV infection can risk factors and outcomes attributable

126 Congenital CMV infection (cCMV) is the most common congenital infec

127 er it poses an increased risk for congenital CMV infection (cCMV).

128 protect the fetus from acquiring congenital CMV infection (cCMV).

129 Congenital CMV infection (cCMVi) affects 0.5-1% of all live births

130 Studies of congenital CMV infection (cCMVi) pathogenesis are complicated by th

131 Overall, 172 cleared their CMV infection (CMV DNA <200 copies/mL) within 6 weeks.

132 vertant T cells in the context of persistent CMV infection, combined with lack of regulatory T cells,

133 leading to a higher risk of cytomegalovirus (CMV) infection compared with anti-interleukin 2 receptor

134 Human cytomegalovirus (CMV) infections comprise a leading cause of newborn impa

135 ulation significantly associated with latent CMV infection, confirming the findings in previous studi

136 Progression to clinically significant CMV infection (CS-CMVi) was defined as a CMV load >1000

137 ed from subjects with clinically significant CMV infection (CS-CMVi).

138 patients at risk for clinically significant CMV infection (CS-CMVi).

139 ts who completed treatment for an episode of CMV infection/disease were included.

140 previously shown that acute cytomegalovirus (CMV) infection disrupts the induction of transplantation

141 After a primary maternal CMV infection during pregnancy infants are at risk for d

142 Cytomegalovirus (CMV) infection during fetal life causes severe symptoms

143 After primary maternal cytomegalovirus (CMV) infection during pregnancy, infants are at risk for

144 ents received maribavir for cytomegalovirus (CMV) infection failing conventional therapy (trial 202)

145 who received letermovir for the treatment of CMV infection from November 2017 to October 2018.

146 me-linked immunospot (ELISPOT) assay and for CMV infection from the period before transplantation to

147 SOT) recipients who control cytomegalovirus (CMV) infection from those who progress to CMV-disease (C

148 Chronic CMV infection further impairs immune function and is ass

149 hy 51-year-old man from Iran who after acute CMV infection had an onset of progressive CMV disease th

150 ess, recent developments in the treatment of CMV infections have resulted in improved human health an

151 ified immunosuppression for graft rejection, CMV infection, higher dose of corticosteroids, or prolon

152 kidney recipients at high risk of developing CMV infection if not receiving T-cell-depleting antibodi

153 east 6 months posttransplant, and subsequent CMV infection in 1976 recipients free of prior CMV infec

154 8(+) T cells from acute/primary into chronic CMV infection in 23 (donor+/recipient-; D+R-) lung trans

155 or, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive recipients of al

156 significantly higher prevalence of in utero CMV infection in ALL cases (n = 268) than healthy contro

157 hymocyte globulin may be important to reduce CMV infection in high-risk serostatus group (D+/R-).

158 The efficiency of primary CMV infection in humans following oral exposure, however

159 romised status; however, data specific to GI-CMV infection in immunocompetent patients are comparativ

160 These observations indicate that oral CMV infection in infants typically begins with a single

161 CMV infection in kidney transplant recipients (KTRs) has

162 vitamin D [25(OH)D] level is associated with CMV infection in kidney transplant recipients.

163 an interferon-gamma release assay to predict CMV infection in kidney transplantation.

164 sible impact of viremia and risk factors for CMV infection in pediatric LT recipients managed with ga

165 nd function of CMV-specific CD8+ T cells and CMV infection in SOT recipients.

166 who had suffered posttransplant symptomatic CMV infection in the cross-sectional study.

167 e primary endpoint that was the incidence of CMV infection in the lung allograft within 18 months of

168 uggesting a role for inadequately controlled CMV infection in the pathogenesis of PHIV comorbidities

169 These findings suggest that active CMV infection in the setting of treated HIV may represen

170 acy of maribavir for preemptive treatment of CMV infection in transplant recipients is not known.

171 nd safety of letermovir for the treatment of CMV infection in transplant recipients remain scarce.

172 effect could increase the risk of congenital CMV infections in populations where primary CMV infectio

173 r >=400 mg twice daily was active against RR CMV infections in transplant recipients; no new safety s

174 We explored the role of cytomegalovirus (CMV) infection in CD8 lymphocytosis and inflammation in

175 roved for the prevention of cytomegalovirus (CMV) infection in hematopoietic stem cell transplant pat

176 Cytomegalovirus (CMV) infection in solid-organ transplantation is associa

177 al (Staphylococcus aureus) and viral (murine CMV) infection in vivo.

178 Cytomegalovirus (CMV) infections in hematopoietic cell transplant (HCT) r

179 vir recently approved for the prophylaxis of CMV-infection in patients after hematopoietic stem cell

180 was well tolerated and effective in treating CMV-infections in lung transplant recipients failing on

181 DR3 sequence (CATWDGPYYKKLF) associated with CMV infection, in addition to 12 highly frequent public

182 V shedding events, which we termed transient CMV infections, in a prospective birth cohort of 30 high

183 in the context of a refractory or resistant CMV infection including asymptomatic CMV viremia (n = 3)

184 in the context of a refractory or resistant CMV infection including asymptomatic CMV viremia (n=3),

185 tic options for drug-resistant or refractory CMV infection, including maribavir, letermovir, and adop

186 cell functions in vivo, in a system of mouse CMV infection, indicated that licensing did not play a m

187 Congenital CMV infection is a leading cause of mental retardation a

188 s the first study to suggest that congenital CMV infection is a risk factor for childhood ALL and is

189 CMV infection is a significant cause of morbidity and mo

190 a better understanding of how natural human CMV infection is acquired.

191 We conclude that CMV infection is associated with asthma and may contribu

192 CMV infection is associated with higher CD8 T-cell count

193 Thus, although the incidence of CMV infection is high during infancy, our data provide a

194 Sustained control of CMV infection is largely accounted for by cellular immun

195 its multiple immunoregulatory effects during CMV infection is not clear.

196 the ability of antibodies to protect against CMV infection is not well characterized.

197 cell hyporesponsive phenotype during murine CMV infection is tissue specific and not cell intrinsic.

198 Congenital cytomegalovirus (CMV) infection is a leading cause of mental retardation

199 Cytomegalovirus (CMV) infection is a major cause of morbidity and mortali

200 Cytomegalovirus (CMV) infection is a risk factor for chronic lung allogra

201 Cytomegalovirus (CMV) infection is a serious complication in immunosuppre

202 Cytomegalovirus (CMV) infection is a significant complication in hematopo

203 ral-resistant or refractory cytomegalovirus (CMV) infection is challenging, and salvage therapies, fo

204 Gastrointestinal (GI) cytomegaloviral (CMV) infection is common among patients with immunocompr

205 The natural history of cytomegalovirus (CMV) infection is complex.

206 The immune response to cytomegalovirus (CMV) infection is highly complex, including humoral, cel

207 Cytomegalovirus (CMV) infection is one of the most common persistent vira

208 Cytomegalovirus (CMV) infection is the most prevalent infectious complica

209 memory inflation, as seen for example after CMV infection, is the maintenance of expanded, functiona

210 hus, although most people eventually acquire CMV infection, it usually requires numerous exposures.

211 rs were not significantly protective against CMV infection later after HCT in both study arms.

212 ute to the control of early cytomegalovirus (CMV) infection, leading to a multiphasic type I interfer

213 Chronic cytomegalovirus (CMV) infection leads to long-term maintenance of extraor

214 CMV infection may contribute to risk for morbid outcomes

215 n immunocompromised individuals, and chronic CMV infection may exacerbate a myriad of inflammatory co

216 CMV infection may fail to respond to commercially availa

217 eting recipients with allograft rejection or CMV infection may reduce the risk of PCP.

218 svirus infections including cytomegalovirus (CMV) infection may be particularly important for telomer

219 We further demonstrated that acute CMV infection-mediated tolerance disruption led to recip

220 pically confirmed ganR-CMV (n = 37) and ganS-CMV infection (n = 109), matched by donor/recipient CMV

221 for patients who experienced a breakthrough CMV infection (n = 24) during prophylaxis (1.94 [1.11-3.

222 for patients who experienced a breakthrough CMV infection (n=24) during prophylaxis (1.94 [1.11- 3.4

223 Cytomegalovirus (CMV) infection negatively influences both short- and lon

224 espite the defect in maturation, upon murine CMV infection, NK cells from NKp46-Cre-Gata3(fl/fl) mice

225 Mortality associated with CMV infection occurred in 4, and CMV infection adversely

226 Approximately one third of CMV infections occurred during the peripartum period, wi

227 Recurrent on-treatment CMV infections occurred in 25 patients; 13 developed mut

228 CMV infections in populations where primary CMV infection occurs early in childhood but could be min

229 Cytomegalovirus (CMV) infection occurs frequently in young children, who,

230 ium was optimized to improve its utility for CMV infection of maize.

231 altered neurodevelopment that follows murine CMV infection of the developing brain and that a subset

232 of neural progenitor cells or in vivo murine CMV infection of the mouse brain.

233 nd VGCV prophylaxis, a significant effect of CMV infection on the risk of CAV was seen only among HTx

234 iclovir prophylaxis, a significant effect of CMV infection on the risk of CAV was seen only among HTx

235 However, in humans, the impact of CMV infection on the structure and diversity of the unde

236 lerance model to examine the impact of acute CMV infection on: (a) disruption of established transpla

237 rophylaxis, particularly among patients with CMV infection or allograft rejection.

238 Patients with CMV infection or disease had lower median absolute lymph

239 ipients with recurrent and/or drug-resistant CMV infection or disease.

240 Of 130 patients tested, 59 had CMV infection or disease.

241 IE1 is expressed earlier than IE2 after CMV infection or MIE gene transfection.

242 ite antiviral treatment; (iv) CMV disease or CMV infection or risk factors, such as CMV-IgG-negative

243 ase, and patients with ganciclovir-resistant CMV infection or who are intolerant to antiviral therapy

244 e mainstay of treatment for cytomegalovirus (CMV) infection or CMV disease.

245 s (P = .03), allograft rejection (P = .001), CMV infection (P = .001), and severe lymphopenia (P = .0

246 Rejection was significantly associated with CMV infection (P = 0.01, odds ratio = 2.61).

247 te rejection (P = 0.02) and cytomegalovirus (CMV) infection (P = 0.03) than controls.

248 cell subsets in response to cytomegalovirus (CMV) infection, paralleling antigen-specific T cell diff

249 To reduce the burden of congenital CMV infection, potential strategies under consideration

250 on after transplantation further defines the CMV infection prediction risk.

251 lin (>10 mg/kg) were associated with a lower CMV infection rate on univariate analysis.

252 ransplant CMI developed significantly higher CMV infection rates than those deemed to be at low risk

253 The impact of belatacept on CMV infection remains understudied.

254 s in preventive strategies, cytomegalovirus (CMV) infection remains a major complication in solid org

255 Cytomegalovirus (CMV) infection remains an important cause of morbidity a

256 Cytomegalovirus (CMV)-infection remains a major cause of morbidity and mo

257 Our findings show that, despite CMV infection reshaping the TRG repertoire, TRG composit

258 recipients of kidney transplants may predict CMV infection resolution and antiviral drug resistance.

259 T cell kinetics in peripheral blood predict CMV infection resolution and emergence of a mutant strai

260 Cytomegalovirus (CMV) infection sometimes causes large expansions of CMV-

261 he Tshipidi study in Botswana, we determined CMV infection status by 6 months of age and compared hos

262 The infants' CMV infection status was not associated with clinical or

263 e mixed efficacy in patients with refractory CMV infection suggesting that letermovir may be a useful

264 Cytomegalovirus (CMV) infections that are refractory or resistant (RR) to

265 vely studied 27 D(+)R(-) LTRs during primary CMV infection to determine whether acute CD4(+) T cell p

266 Greater knowledge of why CMV infection usually fails may provide insight into how

267 suggest that these mAb may protect mice from CMV infection via passive immunity.

268 Time to the incidence of CMV infection (viremia and/or tissue invasive disease) a

269 The median onset to CMV infection was 10.5 months (interquartile range [IQR]

270 Incidence of CMV infection was assessed by periodic measurements of v

271 CMV infection was assessed in 138 breastfed and 134 form

272 In VLBW infants, postnatal CMV infection was associated with increased risk for BPD

273 Postnatal CMV infection was defined as a diagnosis of CMV or detec

274 Clinically relevant CMV infection was defined as either plasma CMV DNAemia >

275 Clinically relevant CMV infection was defined as either plasma CMV DNAemia>=

276 The CMV infection was detected in 48 patients (49%) in the f

277 CMV infection was diagnosed by polymerase chain reaction

278 During the follow-up, clinically relevant CMV infection was diagnosed in 96 (37%) patients and CAV

279 GI-CMV infection was frequently observed among immunocompet

280 CMV infection was monitored by polymerase chain reaction

281 CMV infection was observed in 34 of 210 (16%) with a med

282 The CMV infection was significantly more frequent among adul

283 The only identified risk factor for CMV infection was the donor/recipient serostatus (odds r

284 We hypothesized that early cytomegalovirus (CMV) infection was associated with increased hospitaliza

285 To describe features of postnatal CMV infection, we extracted clinical and laboratory data

286 issue invasive disease) and risk factors for CMV infection were investigated.

287 Patients (n = 118) at risk of CMV infection were randomized 1:2 to either 5 months or

288 nts) with recurrent or ganciclovir-resistant CMV infection were recruited, and 13 of them were treate

289 In contrast, during murine CMV infection, when the TCR is not engaged, IL-12 signal

290 who cleared, but later experienced recurrent CMV infection while on maribavir, 23 had available UL97

291 ibavir resistance in patients with recurrent CMV infection while on therapy, or no response to therap

292 lopment of therapeutics for cytomegalovirus (CMV) infections, while progressing, has not matched the

293 RTANCE Nucleolar biology is important during CMV infection with the nucleolar protein, with nucleolin

294 Second, the treatment of congenital CMV infections with valganciclovir has beneficially impr

295 A total of 107 recipients had a CMV infection within 1 year of a 25(OH)D measurement.

296 a response to treatment had a recurrence of CMV infection within 6 weeks after starting maribavir at

297 approach to CMV prophylaxis and reduces late CMV infection within the lung allograft.

298 xis, a single ATG dose decreased the risk of CMV infection without increasing the risk of AR or compr

299 Developing a vaccine to prevent CMV infection would be extremely valuable but would be f

300 However, what impact acute CMV infection would have on the maintenance of establish